• Mashup Score: 1

    2023 ASH AML Updates [Slides] – Kiran Naqvi MD – MOASC Acute myeloid leukemia updates from our recent ASH from 2022 By Kiran Naqvi, MD Acute myeloid leukemia. These are the updates from our recent ASH from 2022 Acute myeloid leukemia. These are the updates from our recent ASH from 2022. So moving on. The first abs…

    Tweet Tweets with this article
    • 📊 AML updates by Kiran Naqvi MD at #MOASC23 @UCIrvineHealth @MOASC_Office: Oral arsenic, #sorafenib, CLIA-Venetoclax combo show promise in APL, core binding factor AML, FLT3-mutated AML. [Slides] [video]: https://t.co/C92i4Tz89l #AML #ASH2022 https://t.co/49q0InrAxY

  • Mashup Score: 1

    In an interview with Targeted Oncology, Laura Dawson, MD, FRCPC, discussed the results of the phase 3 NRG/RTOG 1112 study of SBRT followed by sorafenib compared with sorafenib alone in locally advanced hepatocellular carcinoma.

    Tweet Tweets with this article
    • In an interview with Targeted Oncology, @ldawsonmd discussed the results of the phase 3 NRG/RTOG 1112 study of #SBRT followed by sorafenib compared with #sorafenib alone in locally advanced hepatocellular carcinoma. #hcc | @pmcancercentre https://t.co/zyBuExImgA https://t.co/AQqhkwNph0

  • Mashup Score: 1

    The phase 3 NRG/RTOG 1112 adds to the body of evidence for the role of external beam radiation, bringing SBRT to the armamentarium of treatment for patients with locally advanced hepatocelluar carcinoma, according to Laura Dawson, MD, FRCPC.

    Tweet Tweets with this article
    • Stereotactic body radiation therapy added to #sorafenib improved survival vs sorafenib alone in patients with locally advanced hepatocellular carcinoma in the phase 3 NRG/RTOG 1112 trial. #GI23 #HCC #lcsm | @ASCO @ldawsonmd @pmcancercentre https://t.co/Fd0rIFzQN2

  • Mashup Score: 0

    During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.

    Tweet Tweets with this article
    • During a live virtual event, @GABOUALFA, MD, discussed the results of the REFLECT trial of #lenvatinib vs #sorafenib and the LEAP-002 trial of lenvatinib/#pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma. #lcsm #HCC | @MSKCancerCenter https://t.co/6fLE0Xl33W